William Blair Expects Weaker Earnings for CARGO Therapeutics

CARGO Therapeutics, Inc. (NASDAQ:CRGX) – Investment analysts at William Blair dropped their Q1 2025 EPS estimates for shares of CARGO Therapeutics in a research note issued to investors on Thursday, March 13th. William Blair analyst S. Corwin now expects that the company will earn ($0.76) per share for the quarter, down from their previous estimate of ($0.66). William Blair has a “Market Perform” rating on the stock. The consensus estimate for CARGO Therapeutics’ current full-year earnings is ($3.69) per share. William Blair also issued estimates for CARGO Therapeutics’ Q2 2025 earnings at ($0.42) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.39) EPS and FY2025 earnings at ($2.03) EPS.

Several other research firms have also issued reports on CRGX. Jefferies Financial Group lowered shares of CARGO Therapeutics from a “buy” rating to a “hold” rating and reduced their target price for the stock from $32.00 to $3.00 in a report on Thursday, January 30th. JPMorgan Chase & Co. downgraded CARGO Therapeutics from an “overweight” rating to an “underweight” rating in a research note on Thursday, January 30th. Piper Sandler downgraded CARGO Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price target for the stock from $34.00 to $4.00 in a research note on Thursday, January 30th. HC Wainwright downgraded CARGO Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, January 30th. Finally, Truist Financial downgraded CARGO Therapeutics from a “buy” rating to a “hold” rating and dropped their price target for the stock from $32.00 to $7.00 in a research note on Thursday, January 30th. One equities research analyst has rated the stock with a sell rating and six have given a hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $15.00.

CARGO Therapeutics Trading Up 1.9 %

CARGO Therapeutics stock opened at $4.21 on Monday. The firm has a 50 day moving average of $7.13 and a 200 day moving average of $14.55. The firm has a market capitalization of $193.88 million, a price-to-earnings ratio of -0.99 and a beta of 1.65. CARGO Therapeutics has a 12-month low of $3.00 and a 12-month high of $33.84.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Brooklyn Investment Group bought a new position in shares of CARGO Therapeutics during the 4th quarter valued at approximately $27,000. Tower Research Capital LLC TRC boosted its position in shares of CARGO Therapeutics by 565.9% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,800 shares of the company’s stock valued at $84,000 after acquiring an additional 4,929 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new position in shares of CARGO Therapeutics during the 4th quarter valued at approximately $141,000. BNP Paribas Financial Markets boosted its position in shares of CARGO Therapeutics by 437.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,438 shares of the company’s stock valued at $211,000 after acquiring an additional 9,311 shares during the last quarter. Finally, Invesco Ltd. bought a new position in shares of CARGO Therapeutics during the 4th quarter valued at approximately $165,000. 93.16% of the stock is currently owned by institutional investors.

About CARGO Therapeutics

CARGO Therapeutics, Inc, a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.